Home  /  Resource Library  /  Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

Study investigated genetic biomarkers related to prognosis in patients with diffuse large b-cell lymphoma treated with CAR-T therapy.